{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:53:29Z","timestamp":1787313209013,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,22]],"date-time":"2013-07-22T00:00:00Z","timestamp":1374451200000},"content-version":"vor","delay-in-days":112,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.lungcan.2012.12.012","type":"journal-article","created":{"date-parts":[[2013,1,11]],"date-time":"2013-01-11T16:04:19Z","timestamp":1357920259000},"page":"75-80","source":"Crossref","is-referenced-by-count":32,"title":["Clinical outcomes with chemotherapy for advanced thymic carcinoma"],"prefix":"10.1016","volume":"80","author":[{"given":"Yusuke","family":"Okuma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Hosomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisaku","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsunekazu","family":"Hishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiharu","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Shibuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuru","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2012.12.012_bib0005","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ijc.11099","article-title":"Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies","volume":"105","author":"Engels","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0010","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/00000478-199003000-00010","article-title":"Histology of the normal thymus","volume":"14","author":"Suster","year":"1990","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0015","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2559.2000.00846.x","article-title":"Cytokeratin profiles of the thymus and thymomas: histogenetic correlations and proposal for a histological classification of thymomas","volume":"36","author":"Kuo","year":"2000","journal-title":"Histopathology"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0020","first-page":"S1689","article-title":"ITMIG definitions and policies","volume":"6","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0025","article-title":"Thymic carcinoma: a multivariate analysis of factors predictive of survival in 290 patients","author":"Weksler","year":"2012","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0030","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0035","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/1097-0142(19910215)67:4<1025::AID-CNCR2820670427>3.0.CO;2-F","article-title":"Thymic carcinoma. A clinicopathologic study of 60 cases","volume":"67","author":"Suster","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0040","series-title":"WHO international histological classification of tumours","article-title":"Histological typing of tumors of the thymus","author":"Rosai","year":"1999"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0045","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/978-3-642-82480-7_7","article-title":"Pathology of thymic epithelial tumors","volume":"75","author":"Muller-Hermelink","year":"1986","journal-title":"Curr Top Pathol"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0050","series-title":"World Health Organization classification of tumors. Pathology and genetics of tumors of the lung, pleura, thymus and heart","author":"Travis","year":"2004"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0055","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/cncr.10226","article-title":"The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients","volume":"94","author":"Okumura","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0060","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/1097-0142(19940715)74:2<606::AID-CNCR2820740212>3.0.CO;2-T","article-title":"Thymoma. Histologic subclassification is an independent prognostic factor","volume":"74","author":"Quintanilla-Martinez","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0065","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1097\/JTO.0b013e3181e96e30","article-title":"Expression and mutational status of c-kit in thymic epithelial tumors","volume":"5","author":"Petrini","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0070","first-page":"331","article-title":"Thymoma metastasizing to extrathoracic sites. A case report","volume":"84","author":"Nickels","year":"1976","journal-title":"Acta Pathol Microbiol Scand A"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0075","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11060-005-1407-5","article-title":"Cerebral involvement of metastatic thymic carcinoma","volume":"75","author":"Kong","year":"2005","journal-title":"J Neurooncol"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0080","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1097\/JTO.0b013e31822e71c0","article-title":"Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma","volume":"6","author":"Agatsuma","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0085","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/cncr.11606","article-title":"Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma","volume":"98","author":"Yoh","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0090","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.lungcan.2009.03.031","article-title":"Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma","volume":"67","author":"Igawa","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0095","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.lungcan.2011.05.013","article-title":"Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity","volume":"74","author":"Okuma","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0100","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1309\/3PDN-PMT5-EQTM-H0CD","article-title":"Neuroendocrine carcinomas (carcinoid tumor) of the thymus. A clinicopathologic analysis of 80 cases","volume":"114","author":"Moran","year":"2000","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0105","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/1097-0142(19910701)68:1<30::AID-CNCR2820680106>3.0.CO;2-4","article-title":"Chemotherapy for invasive thymoma. A 13-year experience","volume":"68","author":"Fornasiero","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0110","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.1994.12.6.1164","article-title":"Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group","volume":"12","author":"Loehrer","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0115","doi-asserted-by":"crossref","first-page":"S357","DOI":"10.1097\/JTO.0b013e3181f21129","article-title":"The role of chemotherapy in advanced thymoma","volume":"5","author":"Schmitt","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0120","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.lungcan.2007.05.016","article-title":"Multimodal treatment of thymic carcinoma: report of nine cases","volume":"59","author":"Magois","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0125","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0002-9343(80)90472-6","article-title":"Dose: a critical factor in cancer chemotherapy","volume":"69","author":"Frei","year":"1980","journal-title":"Am J Med"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0130","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","article-title":"Analysis of survival by tumor response","volume":"1","author":"Anderson","year":"1983","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0135","first-page":"1331","article-title":"Thymic carcinoma with autoimmune syndrome: successful treatment with weekly infusional high-dose 5-fluorouracil and leucovorin","volume":"17","author":"Hsu","year":"1997","journal-title":"Anticancer Res"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0140","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/JTO.0b013e3181a52e74","article-title":"Thymic small cell carcinoma shows marked response to amrubicin","volume":"4","author":"Igawa","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0145","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.lungcan.2010.09.004","article-title":"S-1 is an active anticancer agent for advanced thymic carcinoma","volume":"70","author":"Okuma","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0150","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdh216","article-title":"Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system","volume":"15","author":"Oberg","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0155","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1056\/NEJM200406173502523","article-title":"Thymic carcinoma with overexpression of mutated KIT and the response to imatinib","volume":"350","author":"Strobel","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0160","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12032-008-9100-0","article-title":"Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report","volume":"26","author":"Li","year":"2009","journal-title":"Med Oncol"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0165","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/sj.bjc.6605740","article-title":"Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience","volume":"103","author":"Strobel","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0170","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdr626","article-title":"Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors","author":"Schirosi","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2012.12.012_bib0175","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1200\/JCO.2008.16.1000","article-title":"Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables","volume":"26","author":"Anderson","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500212006794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500212006794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T11:03:57Z","timestamp":1539947037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500212006794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0169500212006794"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2012.12.012","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}